Hims & Hers Health: Expecting A Healthy Report

Hims & Hers Health (NYSE:HIMS) has slipped back down below $20 after the initial excitement over access to a GLP-1 drug solution has worn off. The online health Source: Finviz Since announcing Q1'24 results in early May, Hims has seen some dramatic news. The online health provider announced the availability of a compound version of Novo Nordisk's (NVO) weight loss medication, and a short report from Hunterbrook Media questioned the business practices of the company. NEW, BIG INVESTIGATION: I felt like death ...